1. Articles in category: Genetics

    1-24 of 206 1 2 3 4 5 6 7 8 9 »
    1. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Apr 27;:

      Authors: Duan XF, Zhao Q

      Abstract Neuroblastomas (NB) are one of the most common extracranial solid tumors in children, and they frequently display high heterogeneity in the disease course. With ongoing research, more information regarding the genetic etiology and molecular mechanisms underlying these contrasting phenotypes is being uncovered.

      Read Full Article
      Mentions: MYCN ATRX
    2. HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      Onco Targets Ther. 2017;10:1969-1975

      Authors: Zhang Z, Zou Y, Zhu J, Zhang R, Yang T, Wang F, Xia H, He J, Feng Z

      Abstract A previous genome-wide association study (GWAS) identified four genetic polymorphisms (rs1027702 near DUSP12, rs10055201 in IL31RA, rs2619046 in DDX4, and rs11037575 in HSD17B12 gene) that were associated with neuroblastoma susceptibility, especially for low-risk subjects. The aim of this study was to examine the association between these four polymorphisms and neuroblastoma susceptibility in a Southern Chinese population composed of 256 cases ...

      Read Full Article
    3. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Mol Oncol. 2017 Apr 22;:

      Authors: Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L

      Read Full Article
      Mentions: ALK
    4. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      Oncogene. 2017 Apr 10;:

      Authors: Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G

      Read Full Article
      Mentions: MYCN
    5. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    6. Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Pediatr Hematol Oncol. 2016 May;33(4):264-75

      Authors: Theruvath J, Russo A, Kron B, Paret C, Wingerter A, El Malki K, Neu MA, Alt F, Staatz G, Stein R, Seidmann L, Prawitt D, Faber J

      Read Full Article
      Mentions: ALK
    7. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    8. The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      Aging (Albany NY). 2017 Mar 08;:

      Authors: He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H

      Abstract TP53, a tumor suppressor gene, plays a critical role in cell cycle control, apoptosis, and DNA damage repair. Previous studies have indicated that the TP53 gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.

      Read Full Article
    9. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.

      Eur J Med Chem. 2017 Feb 27;130:336-345

      Authors: Lelle M, Freidel C, Kaloyanova S, Tabujew I, Schramm A, Musheev M, Niehrs C, Müllen K, Peneva K

      Read Full Article
    10. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    11. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    12. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Eur J Cancer. 2016 Dec 26;72:177-185

      Authors: Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ

      Read Full Article
      Mentions: INRG
    13. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

      Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

      Semin Pediatr Surg. 2016 Oct;25(5):257-264

      Authors: Newman EA, Nuchtern JG

      Abstract Neuroblastoma is an embryonic cancer of neural crest cell lineage, accounting for up to 10% of all pediatric cancer. The clinical course is heterogeneous ranging from spontaneous regression in neonates to life-threatening metastatic disease in older children.

      Read Full Article
      Mentions: Treatment
    14. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.

      "Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor kinase that belongs to the insulin receptor superfamily and has previously been shown to play a role in cell proliferation, migration and invasion in neuroblastoma. Activating ALK mutations are reported in both hereditary and sporadic neuroblastoma tumours, and several ALK inhibitors are currently under clinical evaluation as novel treatments for neuroblastoma. Overall, mutations at codons F1174, R1275 and F1245 together account for ~85% of reported ALK mutations in neuroblastoma. NBLW and NBLW-R are paired cell lines originally derived from an infant with metastatic MYCN amplified Stage IVS (Evans Criteria) neuroblastoma, at diagnosis ...

      Read Full Article
      Mentions: Relapse ALK MYCN
    15. Parents of children with cancer value sequencing results, even if non-actionable

      "There is a general, ethical inclination to be reluctant to disclose sequencing information without clear clinical utility, especially when children are involved," said Dr. Malek, who presented the research. "However, our study showed that parents find this information useful in a much broader way than clinicians might expect," she said.  For example, many parents cited psychological benefits to receiving the information. "Almost all of the parents we interviewed wanted to know where the cancer had come from," Dr. Malek explained. "They hoped that evidence of a genetic cause would show that they had not caused it through any action or ...

      Read Full Article
      Mentions: Genetics
    16. A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group.

      A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group.

      Cancer Causes Control. 2016 Aug 19;

      Authors: Mazul AL, Siega-Riz AM, Weinberg CR, Engel SM, Zou F, Carrier KS, Basta PV, Vaksman Z, Maris JM, Diskin SJ, Maxen C, Naranjo A, Olshan AF

      Read Full Article
      Mentions: COG
    17. Gene Modification of Human Natural Killer Cells Using a Retroviral Vector.

      Gene Modification of Human Natural Killer Cells Using a Retroviral Vector.

      Methods Mol Biol. 2016;1441:203-13

      Authors: Kellner JN, Cruz CR, Bollard CM, Yvon ES

      Abstract As part of the innate immune system, natural killer (NK) cells are regarded as promising effector cells for adoptive cell therapy approaches to treat patients with cancer.

      Read Full Article
    18. Landmark Lions project to provide genome sequencing to hundreds of Aussie kids with cancer

      ( Garvan Institute of Medical Research ) Hundreds of Australian children with high-risk cancer will have access to new genome sequencing technologies that could guide their treatment, following the announcement today of substantial Lions Club funding for the Lions Kids Cancer Genome Project -- an important new component of the Zero Childhood Cancer Program for diagnosis and treatment of childhood cancer.

      Read Full Article
      Mentions: Genetics
    19. Metabolic Adaptation in High-Risk Neuroblastoma Lacking p53

      Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare at diagnosis, but evidence suggests that p53 function is often impaired in relapsed, treatment-resistant disease.

      Read Full Article
      Mentions: Relapse
    1-24 of 206 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) ALK
    2. (1 articles) PHOX2B
    3. (1 articles) ATRX
    4. (1 articles) MYCN
  4. Treatments in the News

    1. (1 articles) Chemotherapy